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PPeripheral Arterial Disease
Baseline Functional Performance
Predicts the Rate of Mobility Loss in
Persons With Peripheral Arterial Disease
Mary M. McDermott, MD,*† Jack M. Guralnik, MD, PHD,‡ Lu Tian, SCD,†
Luigi Ferrucci, MD, PHD,§ Kiang Liu, PHD,† Yihua Liao, MS,† Michael H. Criqui, MD, MPH¶
Chicago, Illinois; Bethesda, Maryland; and San Diego, California
Objectives We compared rates of mobility loss among persons with versus without peripheral arterial disease (PAD). Asso-
ciations between baseline functional performance and mobility loss in persons with and without PAD were stud-
ied.
Background Persons with PAD have poorer functional performance than persons without PAD. The prognostic value of poorer
performance in persons with PAD is unknown.
Methods Participants were 398 persons with and 240 without PAD who were free of mobility impairment at baseline.
Participants were followed for a median of 50 months. Baseline measures included the 6-min walk and the
Short Physical Performance Battery score. Mobility status, assessed annually, was defined as the self-reported
loss of the ability to walk one-quarter mile or walk up and down one flight of stairs without assistance.
Results Adjusting for age and gender, we found that PAD participants had a greater rate of mobility loss than persons
without PAD (hazard ratio [HR] 1.63; 95% confidence interval [CI] 1.03 to 2.56). This difference was not statisti-
cally significant after additional adjustment for baseline performance. Among PAD participants, risk of mobility
loss in the lowest versus the 2 highest quartiles of baseline performance were as follows: HR 9.65 (95% CI 3.35
to 27.77, p  0.001) for the 6-min walk and HR 12.84 (95% CI 4.64 to 35.55, p  0.001) for the Short Physical
Performance Battery when adjusting for confounders.
Conclusions Persons with PAD experience greater mobility loss than persons without PAD. This association was explained by
poorer baseline functional performance among participants with PAD. Poorer lower extremity performance pre-
dicts increased mobility loss in persons with and without PAD. (J Am Coll Cardiol 2007;50:974–82) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.030s
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iower-extremity peripheral arterial disease (PAD) is common
n outpatient settings (1,2). The prevalence of PAD was 29%
n a national study of outpatient medical practices, in which
nkle-brachial index (ABI) screening was performed among
en and women ages 70 and older or age 50 to 69 with a
istory of diabetes or cigarette smoking (1). In a separate study,
he prevalence of PAD was 25% among men and women age
5 and older who were screened (2). In cross-sectional analy-
rom the *Department of Medicine and †Department of Preventive Medicine,
orthwestern University Feinberg School of Medicine, Chicago, Illinois; ‡Labora-
ory of Epidemiology, Demography, and Biometry and the §Laboratory of Clinical
pidemiology, National Institute on Aging, Bethesda, Maryland; and the ¶Depart-
ent of Family and Preventive Medicine, University of California at San Diego, San
iego, California. Supported by grants #R01-HL58099, R01-HL64739, and R01-
L071223 from the National Heart, Lung, and Blood Institute and by grant
RR-00048 from the National Center for Research Resources, NIH. Supported in
art by the Intramural Research Program, National Institute on Aging, NIH.c
Manuscript received February 2, 2007; revised manuscript received May 29, 2007,
ccepted May 30, 2007.es, men and women with PAD have poorer performance on
bjective measures of lower-extremity functioning than per-
ons without PAD (3,4). However, the clinical consequences
nd prognostic significance of functional impairment in per-
ons with PAD are unknown.
A critical factor in an older person’s ability to function
ndependently in the community is mobility, defined as the
bility to walk or climb stairs without assistance (5). Older
eople who lose mobility are less likely to remain in the
ommunity; have greater rates of morbidity, mortality, and
ospitalizations; and experience a poorer quality of life (5,6).
owever, the ability of persons with PAD to maintain
obility in the community over time, compared with those
ithout PAD, is unknown. Few studies of the natural
istory of PAD have been performed to measure disease
rogression (7). Studying associations of PAD with mobil-
ty loss is important to better inform clinicians about the
linical consequences of PAD.
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975JACC Vol. 50, No. 10, 2007 McDermott et al.
September 4, 2007:974–82 Mobility Loss in Peripheral Arterial DiseaseIn a prospective observational study, we studied during
0-month follow-up whether persons with PAD have a
reater rate of mobility loss than persons without PAD. We
ypothesized that persons with PAD would experience greater
ates of mobility loss than persons without PAD. Second, we
tudied whether measures of lower-extremity performance
redict risk of mobility loss in participants with and without
AD. We hypothesized that participants with and without
AD who have poorer lower-extremity performance at
aseline would have a greater risk of mobility loss. Third, we
tudied whether associations of baseline lower-extremity
erformance with mobility loss are similar between partic-
pants with versus without PAD. Fourth, we tested the
ypothesis that associations of PAD with greater mobility
oss compared with persons without PAD are explained by
ifferences in baseline lower-extremity performance be-
ween persons with versus without PAD. Finally, we deter-
ined whether baseline functional performance measures
lso predict objectively assessed functional decline by study-
ng associations of baseline functional performance with
ecoming unable to walk continuously for 6 min without
topping among persons with and without PAD,
espectively.
ethods
tudy overview. The funding source for this study played
o role in the design, conduct, reporting of the study, or
ecision to submit the manuscript. The institutional review
oards of Northwestern University and Catholic Health
artners Hospital approved the protocol. Participants gave
ritten informed consent. Participants were part of the
ALCS (Walking and Leg Circulation Study), a prospec-
ive, observational study designed to identify predictors of
unctional decline in persons with and without PAD (3,4,8).
articipants underwent baseline assessment and returned for
nnual follow-up visits. Participants unable to return for
ollow-up because they were ill or had moved away were
nterviewed by telephone. Mean follow-up was 50 months.
articipant identification. Participants with PAD were
dentified from among consecutive patients age 55 years and
lder diagnosed with PAD in 3 Chicago-area noninvasive
ascular laboratories. Half of the participants without PAD
ere identified from persons with normal lower-extremity
rterial studies at the 3 noninvasive vascular laboratories,
nd one-half were identified from among patients with
ppointments in a large general internal medicine practice at
orthwestern. A few PAD participants were those recruited
rom general internal medicine with a low ABI at their
tudy visit. Exclusion criteria for the WALCS have been
eported and are briefly summarized here (8). Exclusion
riteria included dementia, recent major surgery, above- or
elow-knee amputations, nursing home residence, confined
o a wheelchair, and ABI 1.50. Non–English-speaking
atients were excluded because investigators were not fluent
n non-English languages. Individuals with PAD diagnosed cn the noninvasive vascular labo-
atory were excluded if their
aseline visit ABI indicated ab-
ence of PAD. Patients with a
ormal ABI with prior lower-
xtremity revascularization were
xcluded (n  16) because they
ould not clearly be classified as
AD or non-PAD. Participants
ho were not free of mobility
mpairment at baseline were
xcluded.
BI measurement. A handheld Doppler probe (Nicolet
ascular Pocket Dop II, Nicolet Biomedical Inc., Golden,
olorado) was used to obtain systolic pressures in the right
nd left brachial, dorsalis pedis, and posterior tibial arteries
9,10). Each pressure was measured twice: in the order listed
nd in reverse order. The ABI was calculated by dividing the
ean of the dorsalis pedis and posterior tibial pressures in
ach leg by the mean of the 4 brachial pressures (3,4,8,9).
ero values for the dorsalis pedis and posterior tibial pulses
ere set to missing for the ABI calculation. Average
rachial pressures in the arm with highest pressure were
sed when 1 brachial pressure was higher than the opposite
rachial pressure in both measurement sets and the 2
rachial pressures differed by 10 mm Hg or more in at least
ne measurement set, since in such cases subclavian stenosis
as possible (11). The lowest leg ABI was used in analyses.
omorbidities. Comorbidities assessed were diabetes, an-
ina, myocardial infarction, heart failure, cancer, chronic
ung disease, lower-extremity arthritis, spinal stenosis, spi-
al disk disease, and stroke. Disease-specific algorithms that
ombine data from patient report, medical record review,
edications, laboratory values, and a questionnaire com-
leted by the participant’s primary care physician were used
o verify and document baseline comorbidities, based on
reviously developed criteria (12). The American College of
heumatology criteria were used to diagnose knee and hip
steoarthritis (13,14).
xertional leg symptoms. Leg symptoms were classified
ased on responses to the San Diego Claudication Ques-
ionnaire, according to prior studies (3,4,15).
ther measures. Body mass index (BMI) was calculated as
eight (kilograms)/(height [meters])2. Cigarette smoking
istory was determined with patient report.
unctional measures. 6-MIN WALK. Following a standard-
zed protocol, participants walked up and down a 100-ft
allway for 6 min after instructions to cover as much
istance as possible (16,17). Research staff recorded whether
r not the participant stopped to rest during this test. The
-min walk test was repeated at each annual follow-up visit.
EPEATED CHAIR RISES. Participants sit in a straight-
acked chair with arms folded across their chest and stand
times consecutively as quickly as possible. Time to
Abbreviations
and Acronyms
ABI  ankle-brachial index
BMI  body mass index
PAD  peripheral arterial
disease
SPPB  Short Physical
Performance Battery
WALCS  Walking and Leg
Circulation Studyomplete 5 chair rises was measured.
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Mobility Loss in Peripheral Arterial Disease September 4, 2007:974–82TANDING BALANCE. Participants were asked to hold 3
ncreasingly difficult standing positions for 10 s each: stand-
ng with feet together side-by-side and parallel (side-by-side
tand), standing with feet parallel with the toes of one foot
djacent to and touching the heel of the opposite foot
semi-tandem stand), and standing with one foot directly in
ront of the other (tandem stand) (18,19).
-M WALKING VELOCITY. Walking velocity was measured
ith a 4-m walk performed at “usual” and “fastest” pace. For
he “usual” paced walk, participants were instructed to walk
t their usual pace, “as if going down the street to the store.”
ach walk was performed twice. The faster walk in each pair
as used in analyses (19,20).
HORT PHYSICAL PERFORMANCE BATTERY (SPPB). The
PPB combines data from the usual paced 4-m walking
elocity, time to rise from a seated position 5 times, and
tanding balance. Individuals receive a 0 score for each
ask they are unable to complete. Scores of 1 to 4 are
ssigned for remaining tasks, based upon quartiles of
erformance for 6,000 participants in the Established
opulations for the Epidemiologic Study of the Elderly
18,19). Scores are summed to obtain the SPPB, ranging
rom 0 to 12.
hysical activity and walking exercise frequency. Partici-
ants were asked to report the number of times they went
alking for exercise during the previous week. Participants
ere categorized according to whether they went walking
or exercise 0 times per week, 1 to 2 times per week, or 3
imes per week (20). For physical activity, participants were
sked, “During the last week, how many city blocks or their
quivalent did you walk? Let 12 city blocks equal 1 mile”
21). This measure of patient-reported physical activity is
ighly correlated with vertical accelerometer-measured
hysical activity (21) and is significantly associated with
aseline functional performance (data not shown).
obility measures. At each follow-up visit, participants
ere asked whether they were able to walk a quarter mile
nd whether they could climb up and down one flight of
tairs, selecting one of the following 3 response options for
ach measure: a) “yes, on my own”; b) “yes, with assistance”;
r c) “no, not at all.” Mobility loss was defined as becoming
nable to walk a quarter mile or walk up and down one
ight of stairs without assistance (18,19).
tatistical analyses. Baseline characteristics of participants
ith versus without PAD were compared using general
inear models for continuous variables and chi-square tests
or categorical variables, adjusting for age and gender. For
ox regression analyses, person-time for each participant
as calculated as the number of months from the baseline
isit to the date of the most recent visit (last seen) or the
ate of the visit during which mobility loss was first
eported, whichever came first. Participants who died before
obility loss or who underwent lower-extremity revascular-
zation during follow-up were censored at the time of their
ast interview. Similar methods were used for calculating dime to loss of the ability to walk for 6 min continuously.
ox proportional hazards survival model analyses were
erformed to determine the hazard ratio for mobility loss
etween PAD and non-PAD participants, adjusting for age
nd gender. These analyses were repeated with additional
djustment for baseline performance on each measure of
unctioning.
For PAD and non-PAD participants combined, perfor-
ance on the 6-min walk test, 4-m walking speed (usual
ace), and 4-m walking speed (fast pace) was categorized
nto quartiles. The fourth quartile represented the best
erformance level and the first quartile represented the
oorest performance level. Because of low rates of mobility
oss among participants in the third and fourth quartiles of
erformance at baseline, these 2 quartiles were combined.
o participant had an SPPB score of 0 at baseline. A priori,
he SPPB score was categorized as follows: Category 1:
core  1 to 8; Category 2: score  9 to 10; Category 3:
core  11 to 12. Cox proportional hazards analyses were
sed to compare differences in mobility loss and becoming
nable to walk for 6 min continuously across categories of
aseline performance for participants with and without
AD. The first set of Cox proportional hazard analyses
djusted for age, gender, race, BMI, pack-years of cigarette
moking, walking exercise frequency, and comorbidities
Model 1). Among participants with PAD, Model 1 addi-
ionally adjusted for the ABI and leg symptoms. Model 2
djusted for covariates in Model 1 in addition to physical
ctivity. Analyses were repeated within the entire cohort,
ncluding a test for an interaction between PAD status and
erformance measures in their association with mobility
oss. We tested the proportional hazards assumption for
obility loss using martingale residuals based methods, and
e did not find any evidence of significant deviation from
he proportional hazards assumption (22). Analyses were
erformed using SAS statistical software (version 9.1, SAS
nstitute Inc., Cary, North Carolina).
esults
mong 723 WALCS participants eligible for these analy-
es, including 460 with ABI 0.90, 4 PAD participants
ithout baseline functional performance data were ex-
luded. An additional 42 participants (33 with PAD) were
xcluded because follow-up data on mobility were not
vailable. Of the remaining 423 PAD and 254 non-PAD
articipants, 398 (94.1%) with PAD and 240 (94.5%)
ithout PAD reported no mobility loss at baseline and were
ncluded in analyses.
Average ages of PAD and non-PAD participants were
1.7  8.4 years and 69.3  8.0 years, respectively. The
roportions of women among PAD and non-PAD par-
icipants were 39.7% and 47.1%. Among PAD partici-
ants, 31.9% had classic symptoms of claudication, and
9.1% reported no exertional leg symptoms. The remain-
er had exertional leg symptoms other than claudication.
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September 4, 2007:974–82 Mobility Loss in Peripheral Arterial Diseaseable 1 shows characteristics of PAD and non-PAD
articipants, adjusting for age and gender. Participants
ith PAD had a greater pack-year history of cigarette
moking, greater prevalences of diabetes and cardiac or
erebrovascular diseases, and a lower prevalence of spinal
tenosis compared with participants without PAD. Par-
icipants with PAD walked fewer blocks during the prior
Age- and Gender-Adjusted Characteristicsof Study Participants With and Without PAD
Table 1 Age- and Gender-Adjusted Characteof Study Participants With and With
African-American race, %
Ankle-brachial index
Body mass index, kg/m2
Cigarette smoking (pack-years)
Cardiac or cerebrovascular diseases, %
Cancer, %
Pulmonary disease, %
Diabetes, %
Hip arthritis, %
Knee arthritis, %
Spinal stenosis, %
Disk disease, %
CRP, mg/dl
Number of blocks walked during the past week
6-min walk performance, ft
4-m walk (usual pace), m/s
4-m walk (fast pace), m/s
Short Physical Performance Battery (0 to 12 scale)
Values are expressed as estimate mean and standard error un
percentages. *p  0.05; †p  0.001.
CRP  C-reactive protein; PAD  peripheral arterial disease.
Adjusted Associations of Presence of Peripheraof Mobility or the Ability to Walk Continuously f
Table 2 Adjusted Associations of Presenceof Mobility or the Ability to Walk Co
Mobility loss outcome
Model I*
Model I with additional adjustment for 6-min walk perfor
at baseline
Model I with additional adjustment for usual-paced 4-m
walking velocity
Model I with additional adjustment for fast-paced 4-m wa
velocity
Model I with additional adjustment for the Short Physical
Performance Battery
Loss of ability to walk continuously for 6 min without stopp
Model I*
Model I with additional adjustment for 6-min walk perfor
at baseline
Model I with additional adjustment for usual-paced 4-m
walking velocity
Model I with additional adjustment for fast-paced 4-m wa
velocity
Model I with additional adjustment for the Short Physical
Performance BatteryAnalyses for mobility loss exclude participants with baseline loss of mobility. S
participants who stopped during the 6-min walk test at baseline. *Model I adeek and had significantly poorer performance on mea-
ures of functioning, compared to those without PAD
Table 1).
Adjusting for age and gender, the hazard ratio for
obility loss among PAD vs. non-PAD participants was
.63 (95% confidence interval 1.03 to 2.56, p  0.036).
fter additional adjustment for each performance measure,
s
AD
ticipants With PAD
(n  398)
Participants Without PAD
(n  240)
15.94 17.32
0.65 (0.006)† 1.10 (0.008)†
27.4 (0.24) 28.0 (0.31)
37.7 (1.5)† 17.8 (1.9)†
57.32† 37.33†
14.39 15.82
30.77 32.45
30.65† 15.92†
3.24 2.71
9.73 11.56
9.10 30.36
29.71 31.51
0.56 (0.04) 0.44 (0.06)
36.7 (2.98)* 51.8 (3.85)*
1,170.3 (17.8)† 1,452.6 (23.0)†
0.90 (0.01)† 0.96 (0.01)†
1.23 (0.01)* 1.29 (0.01)*
9.97 (0.10)* 10.36 (0.13)*
therwise indicated. The categorical variables are expressed as
rial Disease and Lossin at Follow-Up (n  638)
ripheral Arterial Disease and Loss
ously for 6 Min at Follow-Up (n  638)
Hazard Ratio 95% Confidence Interval p Value
1.63 1.03–2.56 0.036
1.00 0.63–1.60 0.992
1.22 0.78–1.92 0.385
1.40 0.89–2.21 0.150
1.53 0.93–2.50 0.094
2.17 1.42–3.32 0.0004
1.49 0.97–2.30 0.0715
1.82 1.19–2.80 0.0061
1.92 1.25–2.94 0.0027
2.23 1.43–3.49 0.0004ristic
out P
Par
less ol Arteor 6 M
of Pe
ntinu
mance
lking
ing
mance
lkingimilarly, analyses for the ability to walk for 6 min continuously exclude
justs for age and gender.
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Mobility Loss in Peripheral Arterial Disease September 4, 2007:974–82he association between PAD and mobility loss was atten-
ated and no longer statistically significant (Table 2).
Figure 1 shows the associations between baseline lower-
xtremity performance and mobility loss at 50-month
ollow-up among participants with PAD. Adjusting for age,
ender, race, ABI, BMI, cigarette smoking, leg symptoms,
omorbidities, and walking exercise frequency (Model 1),
oorer performance on each measure of lower-extremity
erformance at baseline was associated with significantly
ncreased rates of mobility loss at follow-up (Fig. 1). These
ndings were not substantially changed after additional
Figure 1 Hazard Ratios for Mobility Loss at 50-Month Follow-U
and Women With PAD, According to Baseline Functio
Model 1: adjusts for age, gender, race, ankle-brachial index, body mass index, pac
bidities. Model 2: Adjusts for variables in model 1 and blocks walked for exercise.
egory 2 (second quartile): 1,001 to 1,304 ft; Category 3 (third and fourth quartil
0.792 m/s; Category 2 (second quartile): 0.792 to 0.915 m/s; Category 3 (th
(lowest quartile): 1.078 m/s; Category 2 (second quartile): 1.078 to 1.274 m/
formance Battery (0 to 12 scale, 12  best)  Category 1: 1 to 8; Category 2: 9
0.05 relative to the highest 2 categories. PAD  peripheral arterial disease.djustment for physical activity (Model 2, Fig. 1). Partici- aants in the poorest quartile of the 6-min walk performance
t baseline had a hazard ratio of 9.65 (95% confidence
nterval 3.35 to 27.77, p  0.001) for mobility loss during
ollow-up, compared with participants in the highest 2
uartiles for baseline performance, adjusting for confound-
rs (Model 2, Fig. 1). Similarly, participants in the lowest
aseline quartiles of performance for the usual paced and
ast-paced 4-m walking speed and the SPPB, respectively,
ad significantly increased rates of mobility loss during
ollow-up, compared with participants in the highest 2
uartiles for these measures (Model 2, Fig. 1). Peripheral
ong Men
erformance
s of cigarette smoking, leg symptoms, walking exercise frequency, and comor-
ories of performance: 6-min walk  Category 1 (lowest quartile): 1,001 ft; Cat-
bined): 1,304 ft. 4-m walk (usual pace)  Category 1 (lowest quartile):
fourth quartiles combined): 0.915 m/s. 4-m walk (fast pace)  Category 1
tegory 3 (third and fourth quartiles combined): 1.274 m/s. Short Physical Per-
Category 3: 11 to 12. *p  0.01 relative to the highest 2 categories; **p p Am
nal P
k-year
Categ
es com
ird and
s; Ca
to 10;rtery disease participants in the second quartile of perfor-
m
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September 4, 2007:974–82 Mobility Loss in Peripheral Arterial Diseaseance for each functional measure had significantly greater
ates of mobility loss compared to PAD participants in the
ighest quartiles of performance at baseline (Model 2,
ig. 1).
Figure 2 shows associations between baseline perfor-
ance and mobility loss among participants without
AD. Adjusting for age, gender, race, BMI, cigarette
moking, comorbidities, and frequency of walking exer-
ise, poorer performance on each baseline measure of
ower extremity functioning was associated with higher
isk of mobility loss among participants without PAD
Figure 2 Hazard Ratios for Mobility Loss at 50-Month Follow-U
and Women Without PAD, According to Baseline Func
Model 1: adjusts for age, gender, race, body mass index, pack-years of cigarette s
in model 1 and blocks walked for exercise. Categories of performance: 6-min walk
1,304 ft; Category 3 (third and fourth quartiles combined): 1,304 ft. 4-m walk
tile): 0.797 to 0.915 m/s; Category 3 (third and fourth quartiles combined): 0
2 (second quartile): 1.078 to 1.274 m/s; Category 3 (third and fourth quartiles
best)  Category 1: 1 to 8; Category 2: 9 to 10; Category 3: 11 to 12. *p  0.05
PAD  peripheral arterial disease.Model 1, Fig. 2). These associations were not substan- cially changed after additional adjustment for physical
ctivity (Model 2, Fig. 2).
We observed no significant interactions between PAD
tatus and functional performance in their associations with
obility loss (data not shown). Figure 3 compares rates of
obility loss between PAD and non-PAD participants
ccording to categories of baseline performance. Within the
owest and highest quartiles of performance, rates of mo-
ility loss were comparable between PAD and non-PAD
articipants. Within the second quartile of baseline perfor-
ance, rates of mobility loss were higher among PAD
ong Men
l Performance
g, walking exercise frequency, and comorbidities. Model 2: adjusts for variables
tegory 1 (lowest quartile): 1,001 ft; Category 2 (second quartile): 1,001 to
pace)  Category 1 (lowest quartile): 0.792 m/s; Category 2 (second quar-
/s. 4-m walk (fast pace)  Category 1 (lowest quartile): 1.078 m/s; Category
ed): 1.274 m/s. Short Physical Performance Battery (0 to 12 scale, 12 
ve to the highest 2 quartiles; **p  0.001 relative to the highest 2 quartiles.p Am
tiona
mokin
 Ca
(usual
.915 m
combin
relatiompared with non-PAD participants (Fig. 3). Data in
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Mobility Loss in Peripheral Arterial Disease September 4, 2007:974–82able 2 and Figure 3 suggest that differences in mobility loss
etween PAD and non-PAD participants over time are
ttributable in part to differences in baseline performance
etween PAD and non-PAD participants.
At baseline, 509 participants (284 with PAD) com-
leted the 6-min walk test without stopping. At 42.8
onths follow-up, 71 PAD participants (25%) and 32
on-PAD participants (14%) became unable to walk for
min continuously (p  0.0026). Among participants
ith PAD, poorer baseline 6-min walk performance and
lower fast-paced 4-m walking velocity were associated
ndependently with increased risk of becoming unable to
alk for 6 min continuously when adjusting for con-
ounders (Table 3). Among participants without PAD,
Figure 3 Rates of Mobility Loss for Participants With and With
According to Baseline Functional Performance Catego
Categories of performance: 6-min walk  Category 1 (lowest quartile): 1,001 ft;
tiles combined): 1,304 ft. 4-m walk (usual pace)  Category 1 (lowest quartile):
and fourth quartiles combined): 0.915 m/s. 4-m walk (fast pace)  Category 1 (
Category 3 (third and fourth quartiles combined): 1.274 m/s. Short Physical Per
10; Category 3: 11 to 12. PAD  peripheral arterial disease.aseline 6-min walk performance, normal-paced 4-m palking velocity, and SPPB scores were each associated
ndependently with increased risk of becoming unable to
alk for 6 min continuously, adjusting for confounders
Table 3). Adjusting for age and gender, the hazard ratio
or loss of the ability to walk continuously for 6 min
mong PAD versus non-PAD participants was 2.17 (95%
onfidence interval 1.42 to 3.32, p  0.0004). After
dditional adjustment for baseline 6-min walk perfor-
ance, the association between PAD and mobility loss
as attenuated and no longer statistically significant
Table 2). However, the association between PAD and
oss of the ability to walk continuously for 6 min
emained statistically significant even after additional
djustment for usual-paced 4-m walking speed, fast-
AD,
Defined for the Entire Cohort
ory 2 (second quartile): 1,001 to 1,304 ft; Category 3 (third and fourth quar-
2 m/s; Category 2 (second quartile): 0.792 to 0.915 m/s; Category 3 (third
t quartile): 1.078 m/s; Category 2 (second quartile): 1.078 to 1.274 m/s;
ce Battery (0 to 12 scale, 12  best)  Category 1: 1 to 8; Category 2: 9 toout P
ries
Categ
0.79
lowes
formanaced 4-m walking speed, and the SPPB (Table 2).
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ur data demonstrate that persons with PAD have an
ncreased rate of mobility loss at 4-year follow-up compared
ith persons without PAD. Because mobility maintenance
s integral to maintenance of functional independence, social
nteractions, and activities of daily living, the increased rate
f mobility loss in persons with PAD has potentially
mportant implications for maintaining functional indepen-
ence in individuals with PAD.
Results presented here demonstrate that simple, objective
easures of lower-extremity performance can be used to
dentify persons with PAD who are at highest risk for
obility loss. Although all participants were free of mobility
mpairment at baseline, a wide range of baseline functional
erformance was observed. The objective measures of per-
ormance detected subclinical deficits among persons with
AD that were associated with mobility loss later. Measures
f lower-extremity performance are reliable and require
inimal time for administration. These results are expected
o be useful to clinicians, who can use these simple tests to
dentify PAD patients who are at increased risk of mobility
oss.
Previous study demonstrated that baseline measures of
unctional performance predict mobility loss, loss of the
bility to perform activities of daily living, and mortality
mong community dwelling older men and women without
AD (18,19). Our study confirms these findings in persons
ithout PAD and provides new information about the
bility of performance based measures to predict mobility
oss in persons with PAD. Results presented here also
djusted Associations of Baseline Functional Performance Measureith Loss of the Ability to Walk Continuously for 6 Min Without St
Table 3 Adjusted Associations of Baseline Functional PerformaWith Loss of the Ability to Walk Continuously for 6 Mi
Participants Wi
Functional Performance
Hazard Ratio
(95% Confidence Interval)
6-min walk test
First quartile (worst) 6.22 (2.63–14.71)†
Second quartile 2.04 (0.90–4.63)
Third and fourth quartiles (best) 1.0 (reference)
Normal-paced 4-min walking velocity
First quartile (worst) 1.56 (0.77–3.17)
Second quartile 1.39 (0.71–2.73)
Third and fourth quartiles (best) 1.0 (reference)
Fast-paced 4-m walking velocity
First quartile (worst) 3.47 (1.61–7.48)¶
Second quartile 2.22 (1.09–4.51)
Third and fourth quartiles (best) 1.0 (reference)
Short Physical Performance Battery
First quartile (worst) 1.65 (0.80–3.43)
Second quartile 1.85 (0.91–3.77)
Third and fourth quartiles (best) 1.0 (reference)
Analyses exclude participants who stopped during the 6-min walk test at baseline. Analyses wer
ardiac or cerebrovascular disease, pulmonary disease, cancer, and blocks walked during the past
ymptoms and the ankle-brachial index. †p  0.001; ‡p  0.003; §p  0.013; p  0.03; ¶p uggest that the increased mobility loss in persons with oAD is largely attributable to the poorer baseline functional
erformance among persons with PAD compared with
hose without PAD. The greater incidence of mobility loss
or PAD participants compared with those without PAD
as no longer statistically significant after adjusting for
ifferences in baseline lower-extremity performance be-
ween participants with versus without PAD. Further study
s needed to determine whether performance based mea-
ures also predict mortality and hospitalization in persons
ith PAD.
Findings regarding baseline functional performance and
oss of the ability to walk continuously for 6 min without
topping differed from those with mobility loss. Among
ersons with and without PAD, performance on some, but
ot all, baseline functional performance measures predicted
oss of the ability to walk for 6 min continuously without
topping. The higher rate of losing the ability to walk for 6
in continuously among participants with PAD compared
ith those without PAD remained statistically significant,
ven after adjusting for usual-paced 4-m walking speed,
ast-paced 4-m walking speed, and the SPPB. Patient-
eported mobility loss and objectively measured loss of the
bility to walk continuously for 6 min are distinct outcomes.
potential explanation for lack of full concordance in
ndings between these 2 outcomes is that patients with the
reatest disability at follow-up may have provided data on
obility loss in a telephone interview, but may have been
oo ill to return for a 6-min walk test.
As indicated in recently published clinical practice guide-
ines, few data are available to document the natural history
g (n  509)*
Measures
hout Stopping (n  509)*
Participants Without PAD
p Trend
Hazard Ratio
(95% Confidence Interval) p Trend
p  0.001 5.18 (1.78–15.05)‡ 0.0004
0.92 (0.27–3.19)
1.0 (reference)
0.220 3.43 (1.29–9.09)§ 0.009
0.61 (0.18–2.04)
1.0 (reference)
0.0015 1.99 (0.66–5.97) 0.227
1.21 (0.43–3.43)
1.0 (reference)
0.171 3.90 (1.45–10.49)# 0.007
0.96 (0.30–3.09)
1.0 (reference)
ted for age, gender, race, body mass index, pack-years of smoking, exercise frequency, diabetes,
nalyses involving participants with peripheral artery disease were additionally adjusted for the leg
#p  0.007.soppin
nce
n Wit
th PAD
e adjusf lower-extremity outcomes in persons with PAD (7). On
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Mobility Loss in Peripheral Arterial Disease September 4, 2007:974–82he basis of available data, current clinical practice guidelines
eport that claudication symptoms in persons with PAD
ypically remain stable and do not worsen at a rapid rate (7).
owever, stabilization of leg symptoms over time may not
e indicative of mobility preservation because some persons
ith PAD may restrict their physical activity to avoid leg
ymptoms. Further study is needed to determine whether
mproving lower-extremity functioning with interventions
uch as exercise, medical therapy, or revascularization can
educe rates of mobility loss among persons with PAD.
ata presented here suggest that these interventions could
e targeted toward PAD patients with poorer performance
n objective measures of functioning.
tudy limitations. Our study has limitations. First, partic-
pants were identified from academic medical centers, and it
s unclear whether our findings are generalizable to individ-
als outside of academic medical centers. However, there is
o reason to believe that the relationships presented here
ight differ for persons outside academic medical centers.
econd, this study was observational. Associations between
unctional impairment and mobility loss cannot be con-
trued as causal.
onclusions
ersons with PAD have a greater incidence of mobility loss
ompared with individuals without PAD. Differences in
ates of mobility loss between persons with versus without
AD appear to be primarily related to greater baseline
unctional impairment in persons with versus without PAD.
imple, objective measures of functional performance,
hich can be readily performed in the office setting, can be
sed to identify PAD persons at highest risk for mobility
oss.
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